Paul S M, Syapin P J, Paugh B A, Moncada V, Skolnick P
Nature. 1979 Oct 25;281(5733):688-9. doi: 10.1038/281688a0.
The benzodiazepines are potent anticonvulsants for a wide variety of experimental and clinical seizure disorders. The demonstration of saturable, high-affinity and stereospecific binding sites for the benzodiazepines in the mammalian central nervous system suggests the presence of pharmacological receptors mediating the anticonvulsant properties of these compounds. The good correlation between the anticonvulsant potencies of a series of benzodiazepines and their ability to inhibit 3H-diazepam binding in vitro further supports this hypothesis, but evidence for a direct interaction between benzodiazepines and their receptors, and a subsequent inhibition of seizure activity (or elevation of seizure threshold) is lacking. Recent reports from our laboratory and others have demonstrated the feasibility of labelling benzodiazepine receptors in vivo following parental administration of tritiated benzodiazepine. This technique permits one to study the relationship between the anticonvulsant activity of the benzodiazepines in vivo and the number of 'drug-occupied' receptors in vitro. We now report that there is an excellent correlation between benzodiazepine receptor occupancy by diazepam and protection against pentylenetetrazol-induced seizures. Furthermore, these results demonstrate that only a small fraction of benzodiazepine receptors need be occupied to produce a complete anticonvulsant effect.
苯二氮卓类药物对多种实验性和临床癫痫发作疾病具有强效抗惊厥作用。在哺乳动物中枢神经系统中,苯二氮卓类药物可饱和、高亲和力和立体特异性结合位点的存在表明,介导这些化合物抗惊厥特性的药理学受体是存在的。一系列苯二氮卓类药物的抗惊厥效力与其体外抑制3H-地西泮结合的能力之间的良好相关性进一步支持了这一假说,但缺乏苯二氮卓类药物与其受体之间直接相互作用以及随后抑制癫痫活动(或提高癫痫阈值)的证据。我们实验室和其他实验室最近的报告表明,静脉注射氚标记的苯二氮卓类药物后,在体内标记苯二氮卓类受体是可行的。这项技术使人们能够研究苯二氮卓类药物在体内的抗惊厥活性与体外“药物占据”受体数量之间的关系。我们现在报告,地西泮对苯二氮卓类受体的占有率与对戊四氮诱导的癫痫发作的保护作用之间存在极好的相关性。此外,这些结果表明,只需占据一小部分苯二氮卓类受体就能产生完全的抗惊厥作用。